Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
Trial details
- Registry ID
- NCT07671911
- Drugs studied
- NAL ER
TrialRedline tracks 10 clinical trials sponsored by Trevi Therapeutics: 1 Phase 3, 5 Phase 2 / 3, 4 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) TabletsNCT07671911 | NAL ER | Recruiting | 2028-06Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| PRISM Study-Pruritus Relief Through Itch Scratch ModulationNCT03497975 | Nalbuphine ER Tablets | Completed | 2022-05-10Actual |
| Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo NodularisNCT02174432 | nalbuphine HCl ER | Completed | 2017-09-03Actual |
| Study of Nalbuphine HCl ER Tablets in Patients With Prurigo NodularisNCT02174419 | nalbuphine HCl ER tablets 180 mg BID, nalbuphine HCl ER tablets 90 mg BID | Completed | 2016-08Actual |
| Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic PruritusNCT02143973 | nalbuphine HCl ER | Completed | 2016-01Actual |
| Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic PruritusNCT02143648 | nalbuphine HCl ER tablets 120mg BID, nalbuphine HCl ER tablets 60 mg BID | Completed | 2015-07Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)NCT07671924 | NAL ER | Recruiting | 2027-09Estimated |
| Cough Reduction in IPF With Nalbuphine ERNCT05964335 | NAL ER | Completed | 2025-04-24Actual |
| Refractory Chronic Cough Improvement Via NAL ER (RIVER)NCT05962151 | NAL ER | Completed | 2025-01-06Actual |
| A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of CoughNCT04030026 | NAL ER | Completed | 2022-05-27Actual |
Names as written in the registry records.
NCT07671911 · Trevi Therapeutics
Before: Not yet recruiting. After: Recruiting.
NCT07671924 · Trevi Therapeutics
Before: Not yet recruiting. After: Recruiting.